Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Many patients with HR+, HER2− early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few ye...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Johnston, Stephen R. D., Harbeck, Nadia, Hegg, Roberto, Toi, Masakazu, Martin, Miguel, Shao, Zhi Min, Zhang, Qing Yuan, Martinez Rodriguez, Jorge Luis, Campone, Mario, Hamilton, Erika, Sohn, Joohyuk, Guarneri, Valentina, Okada, Morihito, Boyle, Frances, Neven, Patrick, Cortés, Javier, Huober, Jens, Wardley, Andrew, Tolaney, Sara M., Cicin, Irfan, Smith, Ian C., Frenzel, Martin, Headley, Desirée, Wei, Ran, San Antonio, Belen, Hulstijn, Maarten, Cox, Joanne, O’Shaughnessy, Joyce, Rastogi, Priya
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2020
Soggetti:
RAPID COMMUNICATIONS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768339/
https://ncbi.nlm.nih.gov/pubmed/32954927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02514
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi